invios-Logo-RGB-small.jpg
APEIRON Respiratory Therapies announces positive results from Phase I trial of inhaled APN01
03 nov. 2022 03h00 HE | invIOs GmbH
Administration of aerosolized APN01 shown to be safe and well tolerated at all dose levels, with no adverse events above Grade 2Investigators recommend further development of inhaled APN01, which may...
Taconic_Logo_Vert_Process_Medium resize.jpg
Taconic Biosciences Launches New COVID-19 Mouse Model
29 avr. 2021 09h00 HE | Taconic Biosciences
RENSSELAER, N.Y., April 29, 2021 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the launch of a new COVID-19 mouse model. This...
TrevenaLogo.jpg
Trevena Announces Collaboration with Imperial College London to Evaluate TRV027 in COVID-19 Patients
02 juin 2020 07h00 HE | Trevena Inc.
-- TRV027 is a novel AT1 receptor selective agonist with the potential to treat acute lung injury and ARDS Robust clinical development history with well-characterized PK and demonstrated safety in...